Russell Investments Group
ARQT icon

Russell Investments Group’s Arcutis Biotherapeutics ARQT Stock Holding History

Russell Investments Group’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$884K Sell
33,725
-28,520
-46% -$664K ﹤0.01% 2521
2026
Q1 		$1.47M Sell
62,245
-15,812
-20% -$404K ﹤0.01% 2033
2025
Q4 		$2.27M Buy
78,057
+55,961
+253% +$1.43M ﹤0.01% 1804
2025
Q3 		$417K Buy
22,096
+10,906
+97% +$172K ﹤0.01% 2548
2025
Q2 		$157K Buy
11,190
+10,950
+4,563% +$154K ﹤0.01% 2708
2025
Q1 		$3.75K Hold
240
– – ﹤0.01% 3408
2024
Q4 		$3.34K Sell
240
-9,144
-97% -$100K ﹤0.01% 3358
2024
Q3 		$87.3K Buy
9,384
+8,381
+836% +$82.7K ﹤0.01% 2686
2024
Q2 		$9.33K Buy
1,003
+982
+4,676% +$8.88K ﹤0.01% 3091
2024
Q1 		$208 Buy
+21
New +$157 ﹤0.01% 3276
2023
Q1 		– Sell
-15,972
Closed -$236K – 3293
2022
Q4 		$236K Buy
15,972
+2,774
+21% +$48.5K ﹤0.01% 2529
2022
Q3 		$251K Buy
+13,198
New +$299K ﹤0.01% 2487
2021
Q1 		– Sell
-1,200
Closed -$33K – 3097
2020
Q4 		$33K Sell
1,200
-400
-25% -$9.8K ﹤0.01% 2951
2020
Q3 		$46K Buy
+1,600
New +$42.7K ﹤0.01% 3081

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Russell Investments Group's ARQT Position: Q2 2026 in Review

Russell Investments Group reduced its Arcutis Biotherapeutics (ARQT) stake by 46% in Q2 2026, selling an estimated $664K and leaving 33,725 shares worth $884K. The position accounts for ﹤0.01% of the portfolio, ranked #2521.

Russell Investments Group first reported a position in ARQT in Q3 2020 and has held it in 14 quarters since. The position peaked at $2.27M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Russell Investments Group held 33,725 shares of Arcutis Biotherapeutics worth $884K as of Q2 2026.
  • Russell Investments Group sold 28,520 Arcutis Biotherapeutics shares in Q2 2026, an estimated $664K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #2521 holding.
  • Russell Investments Group first reported a position in Arcutis Biotherapeutics in Q3 2020 and has held it in 14 quarters since.
  • Russell Investments Group's Arcutis Biotherapeutics position peaked at $2.27M in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.